Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00048958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 394 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    4 amendments

    4 re-verifications since 2019-01-22, no change to tracked fields

    v391-v394

  2. Minor

    Site details revised at 1 of 137 sites

    Study Status, Study Design, Contacts/Locationsv390

  3. Minor

    Trial status: Recruiting to Active, Not Recruiting

    Site details revised at 137 of 137 sites

    Study Status, Contacts/Locationsv389

  4. Minor

    Study Status, Outcome Measures

    Re-verified, no change to tracked fields

    v388

  5. Notable

    Phase: Not applicable to Not specified

    Lead sponsor: Cancer and Leukemia Group B to Alliance for Clinical Trials in Oncology; Trial status: Withdrawn to Recruiting; Primary completion date: Jul 2005 to Jan 2100; and 7 more

    Show all 11 changes in this update
    • Notable Phase: Not applicable to Not specified
    • Notable Lead sponsor: Cancer and Leukemia Group B to Alliance for Clinical Trials in Oncology
    • Notable Trial status: Withdrawn to Recruiting
    • Notable Primary completion date: Jul 2005 to Jan 2100
    • Minor Enrollment target: 0 to 9000
    • Minor Interventions: chromosomal translocation analysis (Genetic), cytogenetic analysis (Genetic) to cytogenetic analysis (Genetic)
    • Minor Eligibility criteria shortened, about 37 words
      Show what changed
      DISEASEPatients CHARACTERISTICS:from adjuncts are eligible if the Main Member Cytogenetics laboratory has agreed to process samples from that adjunct. MustWithin enroll (within 1one month of registration on thisCALGB study)8461, onregister onto a CALGB treatment study for previously untreated acute myeloid leukemiaAML, acuteALL, lymphoblastic leukemiaMDS, or myelodysplasticMM syndromespatients. PatientsSimultaneously enrolled on CLB-100001 (previously treated or untreated multiple myeloma) must enroll on this study Simultaneouswith registration on CLB-9665CALGB (8461, register patients within [...] [...]
    • Minor Study description shortened, about 172 words
      Show what changed
      OBJECTIVES: Determine the incidence of chromosomal abnormalities in patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, or multiple myeloma. Correlate specific chromosomal abnormalities with clinical and laboratory parameters in these patients. Correlate sp [...]
    • Minor Site details revised at 137 of 137 sites
    • Minor Study title shortened, about 8 words
      Show what changed
      GeneticCytogenetic StudyStudies of Patients Within Acute MyeloidLeukemia Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, orand Multiple Myeloma
    • Minor Study arms: 0 to 1

    Study Identification, Study Status, Sponsor/Collaborators, Oversight, Study Description, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locationsv387

Show 42 earlier versions

  1. Stopped

    Trial status: Recruiting to Withdrawn

    Enrollment target: estimated 6400 to confirmed 0; Study sites: 140 to 137

    Study Identification, Study Status, Sponsor/Collaborators, Study Design, Contacts/Locationsv386

  2. Minor

    Study sites: 139 to 140

    Study Status, Conditions, Contacts/Locationsv385

  3. Minor

    Study sites: 142 to 139

    Study Status, Contacts/Locationsv384

  4. Minor

    Study sites: 143 to 142

    Study Status, Contacts/Locationsv383

  5. Minor

    Site contacts updated at 1 of 143 sites

    Study Status, Contacts/Locationsv382

  6. Minor

    Study sites: 142 to 143

    Study Status, Contacts/Locationsv381

  7. Minor

    Study sites revised (142)

    Show what changed: Study sites
    Union Hospital Cancerof ProgramCecil at Union HospitalCounty

    Study Status, Contacts/Locationsv380

  8. Minor

    Study sites: 141 to 142

    Study Status, Contacts/Locationsv379

  9. Minor

    Study sites revised (141)

    Show what changed: Study sites
    BatteOSF CancerHoly Center at NortheastFamily Medical Center

    Study Status, Contacts/Locationsv378

  10. Minor

    Study sites: 142 to 141

    Study Status, Contacts/Locationsv377

  11. Minor

    Study sites: 143 to 142

    Study Status, Conditions, Contacts/Locationsv376

  12. Minor

    Study sites: 141 to 143

    Study Status, Contacts/Locationsv375

  13. Minor

    Study sites: 143 to 141

    Study Status, Contacts/Locationsv374

  14. Minor

    Study sites: 144 to 143

    Study Status, Contacts/Locationsv373

  15. Minor

    Study sites: 143 to 144

    Study Status, Contacts/Locationsv372

  16. Minor

    Study sites: 142 to 143

    Study Status, Contacts/Locationsv371

  17. Minor

    Study sites: 143 to 142

    Study Status, Contacts/Locationsv370

  18. Minor

    Study sites: 141 to 143

    Study Status, Contacts/Locationsv369

  19. Minor

    Study sites: 142 to 141

    Study Status, Contacts/Locationsv368

  20. Minor

    Study sites: 141 to 142

    Study Status, Contacts/Locationsv367

  21. Minor

    Study sites: 142 to 141

    Study Status, Contacts/Locationsv366

  22. Minor

    Study sites: 141 to 142

    Study Status, Contacts/Locationsv365

  23. Minor

    Study sites: 142 to 141

    Study Status, Contacts/Locationsv364

  24. Minor

    Study sites: 143 to 142

    Study Status, Contacts/Locationsv363

  25. Minor

    Study sites: 142 to 143

    Study Status, Contacts/Locationsv362

  26. Minor

    Study sites: 143 to 142

    Study Status, Contacts/Locationsv361

  27. Minor

    Study sites: 142 to 143

    Study Status, Contacts/Locationsv360

  28. Minor

    Study sites: 143 to 142

    Study Status, Contacts/Locationsv359

  29. Minor

    Study sites: 142 to 143

    Study Status, Contacts/Locationsv358

  30. Minor

    Study sites: 144 to 142

    Study Status, Contacts/Locationsv357

  31. Minor

    Study sites: 143 to 144

    Study Status, Contacts/Locationsv356

  32. Minor

    Study sites revised (143)

    Show what changed: Study sites
    GalesburgUAB CottageComprehensive HospitalCancer Center PardeeSaint MemorialJoseph HospitalOncology, Incorporated

    Study Status, Contacts/Locationsv355

  33. Minor

    Study sites: 145 to 143

    Study Status, Contacts/Locationsv354

  34. Minor

    Study sites: 147 to 145

    Study Status, Contacts/Locationsv353

  35. Minor

    Study sites: 146 to 147

    Study Status, Contacts/Locationsv352

  36. Minor

    Study sites: 147 to 146

    Study Status, Contacts/Locationsv351

  37. Minor

    Study sites: 151 to 147

    Study Status, Contacts/Locationsv350

  38. Minor

    Study sites: 150 to 151

    Study Status, Contacts/Locationsv349

  39. Minor

    Study sites: 151 to 150

    Study Status, Contacts/Locationsv348

  40. Minor

    Study sites: 149 to 151

    Study Status, Contacts/Locationsv347

  41. Minor

    Study sites: 150 to 149

    Study Status, Contacts/Locationsv346

  42. Minor

    Study sites: 151 to 150

    Study Status, Contacts/Locationsv345

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
Trial Details
NCT Number NCT00048958
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Enrollment 9,000 participants
Start Date
Primary Completion (estimated)
Updated on ClinicalTrials.gov